BioNexus Gene Lab (NASDAQ:BGLC) Shares Down 0.2% – Should You Sell?

BioNexus Gene Lab Corp. (NASDAQ:BGLC)’s stock price was down 0.2% during mid-day trading on Friday . The company traded as low as $4.02 and last traded at $4.14. Approximately 4,725 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 205,225 shares. The stock had previously closed at $4.15.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNexus Gene Lab in a report on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

BioNexus Gene Lab Stock Down 0.2%

The company has a 50 day simple moving average of $4.64 and a 200 day simple moving average of $4.94. The company has a market capitalization of $9.77 million, a price-to-earnings ratio of -5.45 and a beta of 5.24.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.